Till Kasch

Research Interest

 

Publications

Hank, E. C.; Sai, M.; Kasch, T.; Meijer, I.; Marschner, J. A.; Merk, D. Development of Tailless Homologue (TLX) Agonist Chemical Tools. J. Med. Chem., 2024. DOI

Willems, S.; Busch, R.; Nawa, F.; Ballarotto, M.; Lillich, F.; Kasch, T.; López-García, Ú.; Marschner, J. A.; Rüger, L.; Renelt, B.; Ohrndorf, J.; Arifi, S.; Zaienne, D.; Proschak, E.; Pabel, J.; Merk, D. Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism. J. Med. Chem., 2024, 67, 13324–13348. DOI

Sai, M.; Hank, E. C.; Lewandowski, M.; Kasch, T.; Marschner, J. A.; Merk, D. Development of Potent and Selective Nurr1 Agonists from Amodiaquine By Scaffold Hopping and Fragment Growing. Commun. Chem., 2024, 7, 149. DOI

Lewandowski, M.; Carmina, M.; Knümann, L.; Sai, M.; Willems, S.; Kasch, T.; Pollinger, J.; Knapp, S.; Marschner, J. A.; Chaikuad, A.; Merk, D. Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties. J. Med. Chem., 2024, 67, 2152–2164. DOI

Adouvi, G.; Nawa, F.; Ballarotto, M.; Rüger, L. A.; Knümann, L.; Kasch, T.; Arifi, S.; Schubert-Zsilavecz, M.; Willems, S.; Marschner, J. A.; Pabel, J.; Merk, D. Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist Potency. J. Med. Chem., 2023, 66, 16762–16771. DOI